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ABSTRACT 
The tumor suppressor p53, guardian of the genome, is induced and activated by cellular 
stress signals such as DNA damage, hypoxia and activation of oncogenes. p53 
upregulates downstream target genes, that are involved in cell cycle arrest, senescence, 
apoptosis, etc. Mutations in p53 occur frequently (around 50%) in many human tumors. 
Tumors with p53 mutations often show increased resistance to chemotherapy, since 
many anti-cancer drugs induce p53-dependent apoptosis though DNA damage. Thus 
restoration of wild type function to mutant p53 appears as an attractive approach for 
novel cancer therapy.  
 
The low molecular weight compounds PRIMA-1 and PRIMA-1MET were previously 
identified in our laboratory. We have shown that both PRIMA-1 and PRIMA-1MET (as 
denoted APR-246) are converted to methylene quinuclidinone (MQ), that binds 
covalently to the DNA binding domain of mutant p53, restores its wild type function 
and triggers massive apoptosis in cancer cells.  However the exact molecular 
mechanism of the mutant p53-dependent apoptosis induced by these compounds was 
not elucidated. 
 
In paper I, we demonstrate that PRIMA-1MET/ APR-246 triggers the mitochondrial 
apoptosis pathway in mutant p53 expressing cells.  We show that early activation of 
caspase 2, along with induction of wild type p53 target genes PUMA and Bax are 
crucial for triggering mitochondrial apoptosis pathway. In paper II, we show that 
STMA-1, as a Michael acceptor, inhibits cell proliferation and induces apoptosis in 
mutant p53- expressing tumor cells, but not human diploid fibroblasts. The effect of 
STIMA-1 is dependent on thiol modification. 
 
p53 family members p63 and p73, particularly their DNA binding domains share high 
structure similarity to p53. That prompted us to test whether the mutant p53-
reactivating compound PRIMA-1MET/ APR-246 could also rescue mutant forms of p63 
and p73. In paper III and paper IV we show that PRIMA-1MET/ APR-246 enhances 
mutant p63 DNA binding and restores pro-apoptotic functions to mutant p63γ and p73β 
in tumor cells. Mutations in p63 in humans cause several hereditary developmental 
syndromes with impaired limb development and skin differentiation (such as the EEC 
syndrome). We found that treatment with PRIMA-1MET/ APR-246 promotes 
differentiation of mutant p63 expressing keratinocytes isolated from patients with EEC 
syndrome.  
 
In conclusion, PRIMA-1MET/ APR-246 restores wild type function to mutant p53 
family members presumably through interaction with homologous structures in their 
DNA binding domain. Our studies shed further light on the rescue mechanism of 
mutant p53 family members and raise possibilities for treatment of mutant p63 carrying 
development syndromes such as EEC in the future.  
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INTRODUCTION 
 
Cancer 
Cancer is one of the major causes of death worldwide. Tumor cells arise from normal 
cells and acquire proliferation advantages through mutations, deletions, amplifications, 
chromosomal fusions and epigenetic changes such as DNA methylation and histone 
modification, allowing escape from cell cycle checkpoints and tumor suppressor genes 
(pRb, p53), and get unlimited replication potential. At later stages, tumors acquire 
capacity of sustained angiogenesis, tissue invasion and metastasis (Hanahan and 
Weinberg 2000). 
 
Tumor development is a multi-step process with similarities to the Darwinian evolution 
theory.  The accumulation of several critical genetic alternations (three hits) gives cells 
survival and growth advantage, which lead to clonal expansion and tumor development. 
Based on that model, all cells in the tumor are equal in their capacity to maintain the 
neoplastic growth. Recently developed cancer stem cell model suggests that genetic 
alternations may occur in stem cells. The cancer stem cells harboring critical mutations 
in their genome are capable of both self renewal and they are responsible for 
maintaining  of the population pool of growing tumor (Reya et al., 2001).  
 
Factors such as chemical carcinogens, ultra violate light, hereditary mutations, viral 
infection, inflammation and reactive oxygen species produced during metabolism 
contribute to malignant transformation. Major components of a solid tumor are stroma 
cells, immune cells and blood vessels, that could be manipulated by tumor cells and 
create an interactive tumor microenvironment which supplies the tumor with growth 
factors, oxygen and nutrients.  
 
The frequency of different cancer types varies vastly due to environmental factors, diet 
and life style and genetic factors. Highest incidence of breast cancer occurs in Nordic 
Europe, which is associated with many factors including diet, higher child-bearing age, 
and small number of children per woman. Liver cancer is most common in Asia and 
sub-Saharan Africa due to consumption of food contaminated with aflatoxin produced 
by molds growing in nuts and corn and due to chronic hepatitis B and C infections. 
Melanoma is most frequently in Caucasians, caused by lack of skin pigmentation which 
renders skin poorly protected from solar radiation (IARC, http://www-dep.iarc.fr/).  
 
Cancer therapy 
Surgery, chemo therapy, radiation therapy, combination of radiation and bone marrow 
transplantation and hormone therapy are the most well known and established cancer 
treatment. Cancer cells in general proliferate faster than normal cells. 
Chemotherapeutic drugs mainly target proliferating cells. These drugs can be divided 
into alkylating agents, anti-metabolites, mitotic poisons, topoisomerase inhibitors, and 
other anti-tumor agents. They target DNA replication, inhibit synthesis of new DNA 
strands, prevent microtubule assembling/disassembling or they are interfering with 
DNA supercoiling. The disadvantage of chemo therapy and radiation therapy is lack of 
specificity, thus causing severe side effects. Efforts have also been devoted to the  
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development of targeted cancer therapy, including small molecules or antibodies that 
target cancer associated proteins, for instance activated kinases.  
 
Examples of targeted drugs include: Erlotinib or Tarceva (Roche), a tyrosine kinase 
inhibitor, prevents EGF receptor autophosphorylation, subsequently inhibiting 
downstream cell proliferation signaling cascade (application in non-small lung cell 
cancer) (Shepherd et al., 2005). Gleevec or STI571 (Norvatis), a  tyrosine kinase-Bcr-
Abl inhibitor, blocks it’s ATP binding site and stabilizes it as an inactive conformation 
(application in CML) (Weisberg and Griffin 2000). Herceptin, a monoclonal antibody, 
binds and blocks a tyrosine kinase receptor, Her2 (application in advanced breast 
cancer) (Goldenberg 1999). 
 
p53 and its family members p63 and p73 
In late 1979, p53 was identified as a cellular protein which coimmunoprecipitates with 
the SV40 large T-antigen and it was named as p53 since its molecular weight was 
estimated to be around 53 kDa. The p53 gene is located on the short arm of 
chromosome 17p13 (Isobe et al., 1986; Kern et al., 1991; Matlashewski et al., 1984). 
Originally p53 was regarded as an oncogene, since it was able to transform cells 
together with Ras. Eventually it was realized that a mutant form of p53 was used in the 
original experiments and that wild type p53 is rather a tumor suppressor. Loss of p53 
heterozygosity and mutation of p53 was often observed in many cancers (Baker et al., 
1989; Olivier et al., 2002). 
 
Almost 20 years later, p73 and p63 were discovered. p73 is located on chromosome 
1p36, which exhibits frequent loss of heterozygosity in human cancers (Versteeg et al., 
1995). p63 is located in a region on chromosome 3q27-ter that is actually amplified, not 
lost, in various cancers (Hibi et al., 2000; Yang et al., 1998). Evolution analysis 
suggests that p63 is the ancestor of the p53 family and that p53 is the youngest family 
member. In contrast to p53, mutations in p63 and p73 are rare in tumors. Indeed, p63 or 
p73 null mice showed defects in neurological, inflammatory or defect in hair follicles, 
limb and skin development. (Belyi et al., 2010; Yang et al., 2000; Yang et al., 2002). 
 
Structure of p53 
The genomic sequence of p53 is transcribed into an mRNA transcript composed of 11 
exons with first two non-coding exons. mRNA then is translated to a 393 amino acid 
nuclear protein. Studies have also shown p53 has several isoforms due to its alternative 
promoters in the N-terminus and splicing in the C-terminus (Marcel and Hainaut 2009). 
 
The p53 protein contains a transactivation domain, a proline-rich domain, a DNA 
binding domain and an oligomerization (tetramerization) domain (figure 1). The 
transactivatin domain (amino acids 20 to 60) is composed of two subdomains and 
responsible for p53 transactivation activity. There is also a nuclear localization signal 
situated between the DBD and oligomerization domain. A nuclear export and C-
terminal regulatory domains are located at the end of C terminus (Levine and Oren 
2009).  
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Figure 1.  p53 protein structure Adapted and revised from Hainaut et al, 2010, Cold 
Spring Harbor Perspectives in Biology. 
 
The prolin-rich domain consists of five repeats “PXXP” is shown to be implicated in 
the p53 dependent apoptosis (Sakamuro et al., 1997). The oligomerization domain 
(amino acids 320 to 360) is required for formation of dimers and tetramers. Formation 
of tetramer allows higher affinity between p53 and DNA (Chene 2001). The basic 
domain (last 30 amino acids) contains two nuclear localization signals. Post 
translational modifications of this region increase the stability and transactivation 
activity of p53 (Appella and Anderson 2001). Several residues in the C-terminus are 
known to be phosphorylated (Ser315 and 392), acetylated (Lys320, 373 and 382), or 
SUMOylated (Lys386) in response to DNA damage. The N-terminus is more prone to 
be phosphorylated (Ser15 and Ser23). Post translational modifications of p53 may 
affect stability, protein-protein interactions and transcription activity.  
 
DNA binding domain of p53 is located from amino acids 100 to 300. It recognizes a 
DNA binding motif of two PuPuPuC (A/C)(A/C) GPyPyPyPy palindromes separated 
by a 0 to 21 base pair spacer, where Pu is a purine and Py is a pyrimidine (Hoh et al., 
2002). p53 can transactivate specific genes by binding to p53 response elements in their 
promoter regions. The DNA binding domain is composed of three loops (Cho et al., 
1994). The whole structure is maintained by a zinc ion, that binds to the core cysteine 
residues Cys176, 238, 242, and histidine His 179 in the first loop. There are in total 10 
cysteine residues in the DNA binding domain. Strikingly, p53 mutations frequently 
occur in human tumors within the DNA binding domain- hot spots mutations. These 
mutations are structural or DNA contact mutant (figure 1). In most cases, these 
mutations disrupt p53 transcription. This indicates an essential role of p53-dependent  
transcription for p53 as a tumor suppressor.   
p63 and p73 share high structural homology with p53, especially in their DNA-binding 
domains (>60% amino acid identity) (Kaghad et al., 1997; Osada et al., 1998; Schmale 
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and Bamberger 1997; Yang et al. 1998). All three proteins are expressed as several 
isoforms due to alternative promoter usage in the N-terminal region and splicing in the 
C-terminal region (figure 2). The α isoforms of p63 and p73  contain a sterile α motif 
(SAM) in their C-termini, that exerts an autoinhibitory effect on p63/p73 
transactivation and a transcription inhibitory domain, both of which are not present in 
p53 (Belyi et al., ; Takada et al., 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Structure of p53 family members. Adapted from Stiewe et al, 2007, Nature 
review. 
 
Regulation of p53  
The p53 protein has very short half life, due to its negative feedback loop regulator 
MDM2, which is an E3 ligase and is upregulated by p53.  MDM2 gene contains two 
p53 binding elements (Barak and Oren 1992; Chen et al., 1993; Momand et al., 1992). 
It could mono- or poly-ubiquitinate the N-terminus of p53 and transport p53 from the 
nucleus to the cytosol. The ubiquitinated p53 will be recognized by the proteasome and 
get degraded. MDM2 also binds to the p53 transactivation domain, thus inhibiting its 
function (Haupt et al., 1997; Kubbutat et al., 1997; Wu et al., 1993). Deletion of 
MDM2 in mice is lethal during early embryogenesis due to massive apoptosis. This 
phenotype is rescued by double MDM2 and p53 null mice (Jones et al., 1995; Montes 
de Oca Luna et al., 1995). This highlights the critical regulation of p53 by MDM2.  
MDM2 family member MDMX also negatively regulates p53 transcription. It forms 
heterodimers with MDM2, thus stabilizing MDM2 (Kawai et al., 2007). MDMX null 
mice are also lethal and can be rescued by p53 inactivation (Migliorini et al., 2002; 
Parant et al., 2001). 
 
p14ARF, an alternative reading frame protein encoded by INK4A locus, prevents the 
ubiquination of p53 through binding to MDM2 and thus stabilizes p53. p14ARF also 
sequesters MDM2 in nucleoli and prevents the interaction of MDM2 with p53 in 
nucleoplasm (Chin et al., 1998; Gallagher et al., 2006). 
 
In addition to the regulation of p53 protein outlined above, p53 mRNA can be regulated 
by several factors. The p53 target Wig-1 and the human antigen R (HuR) bind to AU- 
rich elements (ARE) in the 3’UTR and stabilize the p53 mRNA (Vilborg et al., 2009; 
Zou et al., 2006). Wrap53 (WD40-encoding RNA antisense to p53) is located on 
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chromosome 17 and overlaps the first exon of p53. Wrap RNA can stabilize p53 
mRNA by interacting with the 5’ UTR (Mahmoudi et al., 2009). 
 
Another aspect is the regulation of p53 mRNA levels by microRNAs and siRNAs. 
MicroRNAs are endogenous RNAs. They are transcribed as precursor microRNAs that 
go through several cleavages to become matured microRNAs. They are incorporated in 
to the RISC complex, containing an Ago protein  and guide the RISC complex to target 
mRNAs, whose 3’UTRs are partially complementary to the miRNA. siRNAs (about 22 
nt), which are complementary to the target mRNAs, cleave and degrade them directly. 
The 3’UTR of p53 is regulated by several microRNAs, such as miR-125a, -125b, -504, 
-30, and -1285 (Hu et al., ; Le et al., 2009; Li et al., ; Tian et al., ; Zhang et al., 2009).  
 
Activation of p53 
Stress signals such as DNA damage, hypoxia, metabolic stress, unstable ribosomal 
biogenesis, or activation of oncogenes cause stabilization of the p53 protein (Vousden 
and Prives 2009; Vousden and Ryan 2009; Zhang and Lu 2009).  
 
When DNA damage occurs, protein complexes accumulate and get activated at the site 
of damage, which leads to activation of kinases. PI3-kinase family members ATM and 
ATR are activated following DNA double or single strand breaks, phosphorylate Chk2 
and Chk1 and subsequently phosphorylate p53, which prevents the interaction between 
p53 and MDM2 , thus preventing degradation of p53 (Bartek and Lukas 2003). DNA-
PK, another member of the PI3-kinase family, can also be activated following DNA 
strand breaks induced by ionizing radiation and stabilizes p53 by phosphorylating the 
MDM2 binding site on p53 (Lees-Miller et al., 1992; Morozov et al., 1994; Shieh et al., 
1997).  
 
As a gate keeper, an important role for p53 is its activation by oncogene expression and 
abnormal cell proliferation. E2F is a cell proliferation-promoting transcription factor. 
The activation of E2F induces genes involved in proliferation. p14ARF is transcribed 
by E2F and stabilizes p53 protein through its interaction with MDM2 (Bates et al., 
1998; Gallagher et al. 2006). Moreover oncogene activation can probably lead to 
aberrant DNA replication and thus activate p53 via the DNA damage response pathway 
that involves ATM/ATR and Chk2/Chk1 (Bartkova et al., 2005; Gorgoulis et al., 2005). 
 
Function of p53 
 
Cell cycle arrest and DNA repair 
Stress signals, such as DNA damage induces cell cycle arrest which allows DNA repair. 
Classical p53 target genes which trigger cell cycle arrest are p21 and 14-3-3σ (el-Deiry 
et al., 1993; Hermeking et al., 1997). p21 binds to and inhibits function of cyclin 
dependent kinase 2 (CDK2), which forms a complex with cyclin E and phosphorylates 
pRb. Once phosphorylated, pRb releases E2F, that will transcribe genes involved in 
DNA replication.  Thus, cells can transit from G1 phase to S (DNA synthesis) phase  
(Abbas and Dutta 2009). 14-3-3σ inhibits CDK1(Cdc2) and thus prevents G2/M cell 
cycle transition (Taylor and Stark 2001). 
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In addition, p53 also plays a role in several types of DNA repair upon strand breaks and 
DNA adduct formation, including nucleotide excision repair (NER) and base excision 
repair (BER) (Ford and Hanawalt 1997; Zhou et al., 2001).  
 
Apoptosis 
p53 induces several target genes involved in extrinsic (death receptor) and intrinsic 
(mitochondrial) apoptosis pathways. Fas receptor is a p53 target gene. Upregulation of 
Fas (the death receptor) by p53 binds with Fas ligand, further activates caspase-8 and 
eventually activates caspase-3, an effector caspase. Caspase-3 together with other 
effector caspases cleave cytoskeleton and cellular proteins and DNA, resulting in DNA 
fragmentation and formation of apoptotic bodies (Muller et al., 1998). p53 induced 
genes, that activate intrinsic apoptosis pathways, include BH3 family apoptotic proteins, 
such as Bax, PUMA and Noxa (Miyashita and Reed 1995; Nakano and Vousden 2001; 
Oda et al., 2000). Noxa and PUMA help Bax translocate to the surface of mitochondria 
from the cytosol and prevent binding of BCL2/ BCLXL to Bax. Bax oligomerizes or 
forms complex with Bak on the surface of mitochondria, it permeabilizes the outer 
mitochondrial membrane, which leads to release of pro-apoptotic proteins such as 
cytochrome c and AIF from mitochondria,. Eventually cytochorome c forms complex 
with procaspase-9 and Apaf-1, that activates caspase-9 which caspase-3 (Fulda and 
Debatin 2006). p53 also induces PIDD, whose C-terminal cleavage product PIDD cc 
forms PIDDsome complex with RAIDD and pro-caspase 2 (Tinel and Tschopp 2004). 
The PIDDsome complex activates caspase-2 that will also target mitochondria (Lassus 
et al., 2002; Robertson et al., 2002).  
 
In addition, p53 can trigger apoptosis independent of transcription. This involves p53 
translocation to mitochondria by the help of  MDM2 and direct targeting mitochondrial 
membrane(Mihara et al., 2003; Speidel 2010).  
 
Senescence 
p53 also is involved in  senescence, an irreversible cell cycle arrest that can be caused 
by a loss of replicative ability due to shortened telomeres, or premature senescence 
signals, such as DNA damage, oxidative stress, nutrients starvation and oncogene 
activation. Cells are still metabolically active, but do not proliferate. Cells become 
enlarged and flattened (Dimri 2005; Goldstein and Singal 1974). Shortening of 
telomeres activates ATM and ATR that will activate p53. Several other p53 target 
genes, including p21 are involved in triggering senescence (Beausejour et al., 2003; 
Evan and d'Adda di Fagagna 2009; Helton and Chen 2007; Zuckerman et al., 2009). 
 
Differentiation and fertility 
p53 can also prevent stem cell self renewal and induce stem cell differentiation, thus 
eliminating defect stem cells that can contribute to the development of tumor (Zhao and 
Xu 2010). It also has been shown that the activation of p53 is one of the bottlenecks for 
reprogramming somatic cells to induced pluripotent stem cells (iPS) (Kawamura et al., 
2009).  
 
Recently p53 has implicated in fertility. LIF, the gene encoding leukemia inhibitory 
factor, a cytokine critical for embryonic implantation, was recently identified as a p53 
transcription target gene. Knocking down p53 decreases both the level and function of 
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LIF in the uterus and decreases embryonic implantation, pregnancy rate and litter size 
in female mice (Hu et al., 2007). 
 
p53 is also involved in such process as metabolism and  preventing pathological 
angiogenesis (Folkman 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. p53 signaling pathways.  
 
The function of p53 family members p63 and p73 
The full-length TAp63 and TAp73 proteins function as transcription factors similar to  
p53 and induce some p53 downstream targets, such as p21, MDM2, GADD45 and Bax 
(Kaghad et al. 1997; Lee and La Thangue 1999; Zhu et al., 1998). However, this 
conclusion is drawn only based on exogenous overexpression studies. The activation of 
endogenous TAp63 so far is only observed in oocytes upon DNA damage stress (Suh et 
al., 2006). 
 
The ∆N isoforms of p63 and p73 that lack the N-terminal transactivation (TA) domain, 
can block the TA activity of the full-length proteins by forming complexes or by 
competing for DNA-binding sites (Grob et al., 2001; Stiewe and Putzer 2002). Recent 
studies have also shown that ∆Np63 and ∆Np73 can activate transcription through an 
additional N-terminal domain and transcribe unique p63 and p73 targets genes: Rad51, 
BRCA2, mre11 and Rad50 involved in DNA repair (Ghioni et al., 2002; Helton et al., 
2006; Lin et al., 2009; Wolff et al., 2009). 
 
Although p63 and p73 are rarely mutated in human tumors (Strano et al., 2001), 
inactivation of p63 or p73 contribute to tumor development in mice, and p63 and p73 
can cooperate with p53 in tumor suppression (Flores et al., 2005; Guo et al., 2009). 
TAp63 knockout mice show enhanced genomic instability and premature aging as well 
as defects in maintaining skin proliferation and differentiation (Su et al., 2009). Mice 
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with an isoform specific deletion of TAp73 show a high incidence of spontaneous 
tumors and increased sensitivity to carcinogens (Tomasini et al., 2008). Methylation-
induced silencing of the TAp73 promoter has been found in lymphoblastic leukemias 
and Burkitt lymphomas (Corn et al., 1999; Kawano et al., 1999). The ∆Np73 and 
TAp73 isoforms are co-upregulated in primary rhabdomyosarcomas and tumor-derived 
cell lines, as compared with normal muscle (Cam et al., 2006). ∆Np73 isoforms are 
expressed at high levels in many different tumor types and are related to poor prognosis 
(Buhlmann et al., 2008). Thus, accumulating evidence clearly indicates that both p63 
and p73 may have a role in tumor development. 
 
Mice null for p73 develop neurological and immunological defects (Nemajerova et al., 
2009; Wilhelm et al., 2010). p63 null mice show craniofacial abnormalities, limb 
truncations, lack of prostate and a complete absence of an epidermis. The mice die soon 
after birth due to dehydration (Candi et al., 2006; Mills et al., 1999; Signoretti et al., 
2000; Yang et al., 1999). Since both mice models die of young age, it is difficult to 
judge the role of p63 and p73 in tumor development. The ∆Np63α protein is highly 
expressed in basal layers of epidermis and TAp63α is only induced in differentiating 
cells, indicating the role in ∆Np63α in stem cell maintenance and role of TA63α in 
differentiation. However, Studies of TAp63 null mice also show that TAp63 is crucial 
for maintenance of the dermal and epidermal stem cell pool as it was shown for wound 
healing and hair growth (Su et al. 2009). The exact functions of p63 isoforms require 
further investigation. 
 
Heterozygous mutations in p63 are associated with several autosomal-dominant 
developmental disorders in humans, including the EEC syndrome (ectrodactyly, 
ectodermal dysplasia, and cleft lip/palate) (Brunner et al., 2002; Celli et al., 1999). 
Interestingly, the amino acid substitutions in mutant p63 in EEC (204, 227, 279, 280, 
and 304) correspond to the hotspot mutations in p53. 
 
Structure of Epidermis  
A fertilized egg undergoes mitotic division, differentiation and eventually forms an 
embryo. During gastrulation and early embryo development, cells form three different 
germ layers: endoderm, mesoderm and ectorderm. Epidermis, stratified upper layer of 
skin, develops from a single layer of multipotent ectoderm cells through asymmetric 
cell divisions (Wilson and Hemmati-Brivanlou 1995). It is composed of basal, spinous, 
granular, transition and terminal differentiated layer (figure 4). Cells in the basal layer 
show the stem cell-like properties and proliferate to maintain a sufficient epidermal cell 
population. Cells from higher layers are more differentiated. The terminal differentiated 
upper layer is developed from cross-linked dead cell envelopes. Thus epidermis 
functions as a physical barrier between the body and the environment for prevention of 
dehydration and infection (Eckert et al., 2005; Schoenwolf G.C. 2001). 
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Figure 4. keratinocyte differentiation. Adapted and revised from Segre J.A., 2006, 
Journal of Clinical Investigation.  
 
Rescue of wild type p53 function in cancer therapy 
 
Activation of wild type p53 
MDM2 gene is amplified in some tumors which result in excessive degradation of wild 
type p53, mitigating its role as tumor suppressor and stress sensor. Several compounds 
were shown to stabilize p53 through disrupting the interaction of p53 and MDM2. 
 
Nutlin, a low molecular weight compound, was identified based on detailed structural 
analysis of the p53-binding pocket in MDM2. It mimics three amino acid residues in 
p53 that fit in the pocket. Thus it prevents ubiquitination of p53 by MDM2 and 
impedes p53 degradation in the proteasome. The prolonged p53 protein half life results 
in upregulation of p53 target genes and triggers cell cycle arrest and apoptosis in wild 
type p53- expressing tumor cells (Vassilev 2004; Vassilev et al., 2004). 
 
RITA was identified by screening an NCI library for compounds inhibiting the 
proliferation of HCT116 cells expressing wild type p53. It binds to p53 N-terminus and 
inhibits its interaction with MDM2 and p300, thus stabilizing p53, which subsequently 
induces apoptosis in wild type p53 expressing cells, but does not affect p53 null or 
HDF cells in vitro and in vivo (Issaeva et al., 2004); (Grinkevich et al., 2009). 
 
Tenovin-1 was identified in a screening of chemical library for compounds which 
engage transcription transactivation of wild type p53 in tumor cells. Tenovin-1 and its 
more water-soluble analog tenovin-6 keep p53 acetylated by inhibiting deacetyleses 
and thus activate p53 transcription. Interestingly, tenovins inhibit p53 null tumor cell 
proliferation by inhibiting the protein deacetylating activity of SirT1 and SirT2 (Lain et 
al., 2008). 
 
Reactivation of mutant p53 
Since p53 is essential for maintaining genome stability and is frequently mutated and 
accumulated in cancer cells, restoring wild type function to mutant p53 is a promising 
strategy to target cancer cells.  
 
  10 
The p53 antibody PAB421 that recognizes a C-terminal epitope and peptide 46, 
corresponding to p53 residue 361-382, were shown to stimulate p53 DNA binding and 
restore its pro-apoptotic function (Hupp et al., 1995; Niewolik et al., 1995; Selivanova 
et al., 1997). CDB3, derived from the p53 binding protein ASPP, binds the p53 DNA 
binding domain, stabilizes it, and enhances p53 transcription activity (Friedler et al., 
2002). However, the exact molecular mechanism involved is still not clear. 
 
Some chemical chaperones, such as polyols (glycerol) and methylamines, are found to 
stabilize wild type p53 conformation in mutant p53 in vitro (Brown et al., 1997; 
Ohnishi et al., 1999; Ohnishi et al., 2002; Welch and Brown 1996). Thus applying 
chemical chaperones is also a possible approach, however, this process requires high 
concentrations, which limits the application of chemical chaperons in the clinic. 
 
Much effort has also been put on screening for small molecular weight compounds that 
can restore wild type conformation to mutant p53.  
 
CP-31398 was identified by Foster et al. in a chemical library screening, aiming at 
stabilizing the active conformation of the p53 DNA binding domain. CP-31398 can 
stabilize wild type p53 conformation in both wild type and mutant p53 cells in vitro and 
in vivo, induce p53 target genes e.g. PUMA, Bax and trigger capase-3 activation and 
apoptosis (Foster et al., 1999; Luu et al., 2002; Tang et al., 2007). However, some p53 
independent cell death was also observed during the treatment (Rippin et al., 2002; 
Wischhusen et al., 2003).  
 
The maleimide molecule, MIRA-1, was identified by screening an NCI library of low 
molecular weight compounds. It suppresses cell proliferation and triggers apoptosis in a 
mutant p53-dependent manner. Due to the presence in its structure of a maleimide 
group, MIRA-1 reacts rapidly with free thiol and amino groups. However, this 
compound is toxic to mice and therefore not suitable for further preclinical 
development (Bykov et al., 2005). 
 
PRIMA-1 was identified by screening the same chemical library. It inhibits cell 
proliferation preferentially in mutant p53-expressing cells (Bykov et al., 2002a; Bykov 
et al., 2002b). Later on, we discovered that PRIMA and its more potent analog 
PRIMA-1MET/APR-246 are converted to methylene quinuclidinone (MQ), a reactive 
electrophil with Michael acceptor activity. We have shown that it binds covalently to 
thiol groups in the mutant p53 DNA binding domain. Our results suggest that such 
modification is responsible for a change in p53 conformation towards wild-type and for 
the restoration of  wild type p53 function and induction of massive apoptosis in mutant 
p53-expressing cells (Lambert et al., ; Lambert et al., 2009; Shen et al., 2008; Zache et 
al., 2008b).  
 
STIMA-1, which has some structural similarities to CP-31398, was identified from a 
small library of molecules in a screening for mutant p53-dependent growth suppression 
in osteosarcoma cells. STIMA-1 has a structural characteristics of a Michael acceptor 
and thus participates in reactions of nucleophilic addition. As a potent electrophil, 
STIMA-1 is prone to react with several potential targets in cells, such as free thiol 
groups. Similar activity was also described for CP-31398, MIRA-1, as well as MQ, the 
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conversion product of PRIMA-1 and PRIMA-1MET/APR-246. However, in vivo 
treatment with STIMA-1  is limited due to its poor solubility (Zache et al., 2008a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Chemical structure of mutant p53 reactivating compounds. 
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AIMS OF THE THESIS 
The general aim of this thesis is to investigate the mechanisms responsible for 
reactivation of mutant p53 by PRIMA-1MET/APR-246 and STIMA-1, and examine the 
effect of PRIMA-1MET/APR-246 on mutant forms of the p53 family members p63 and 
p73. The study may open new therapeutic applications for PRIMA-1MET/APR-246. 
 
Specific aims 
 
Paper I 
To elucidate apoptotic signaling pathways activated in mutant p53-expressing tumor 
cells after PRIMA-1MET treatment. 
 
Paper II 
To characterize STIMA-1, a novel mutant p53 targeting compound 
 
Paper III 
To investigate whether PRIMA-1MET/APR-246 can rescue isoforms of mutant p53 
family members p63 and p73, that share high structural homology with p53. 
 
Paper IV 
To investigate whether PRIMA-1MET/APR-246 can restore wild type function to 
endogenous mutant p63α expressed in EEC syndrome patients. 
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RESULTS AND DISCUSSION 
 
Paper I 
 
PRIMA-1MET induces mitochondrial apoptosis via activation of 
caspase-2.  
 
We previously showed that the low-molecular-weight compound PRIMA-1MET/APR-
246 reactivates mutant p53, induces apoptosis in human tumor cells and inhibits tumor 
xenograft growth in vivo.  
 
In this paper, we investigated the role of rescued mutant p53 by PRIMA-1MET/APR-246 
in the activation of apoptotic signaling pathways. We first observed that PRIMA-
1MET/APR-246 induced mutant p53-dependent loss of mitochondrial membrane 
potential (∆ψm), accumulation of sub-G1 cell population and activation of pan-
caspases in a dose- and time-dependent manner in three cell lines expressing 
endogenous mutant p53 (H1299-His 175, Saos-2-His 273 and SKOV-His 175 ). These 
results indicate induction of apoptosis. ∆ψm and cell survival were not much affected 
in H1299, Saos-2 and SKOV –TA, p53 null cells after PRIMA-1MET/APR-246 
treatment.  
 
To further study the involvement of mitochondria in PRIMA-1MET/APR-246 induced 
apoptosis, we examined the status of cytochrome c in PRIMA-1MET/APR-246-treated 
H1299 and H1299-His175 cells using immunofluorescence staining. We found that 
treatment with PRIMA-1MET/APR-246 triggered release of cytochrome c from 
mitochondria to the cytoplasm in mutant p53 expressing cells. At later time points, 
these cells displayed formation of pyknotic nuclei indicative of apoptosis. Furthermore, 
treatment with PRIMA-1MET/APR-246 in mutant p53 expressing cells induced 
expression of wild type p53 target genes Bax and PUMA, that are know to collaborate 
and target mitochondrial membrane, leading to drop of ∆ψm.  
 
In order to determine the specific capases involved in mitochondria-mediated apoptosis 
induced by PRIMA-1MET/APR-246, we assessed activation of caspase-2, -3, -9 and -8 
by using the fluorogenic caspase substrates. We found that PRIMA-1MET/APR-246 
treatment triggered early activation of caspase-2, followed by activation of caspase-9 
and eventually activation of caspase-3. The inhibition or silencing of caspase-2 can 
block activation of caspase-9 and caspase-3, and attenuates cell death within certain 
time points and concentrations of PRIMA-1MET/APR-246. Interestingly, loss of ∆ψm 
induced by treatment with PRIMA-1MET/APR-246 couldn’t be rescued by inhibition or 
silencing of caspase-2, indicating an existence of alternative upstream signals involved 
in targeting mitochondria. We also observed an induction of full-length PIDD protein 
and its cleavage fragment PIDD-CC in PRIMA-1MET/APR-246-treated H1299-His175 
cells. PIDD is a known p53 target gene and PIDD-CC is involved in a formation of 
PIDDosome complex, which activates  caspase-2.  
 
We also tested the combination of both PUMA siRNA and caspase-2 inhibitor in 
PRIMA-1MET/APR-246-treated H1299-His175 cells. That did not result in any 
additional protection from cell death.  
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In summary, we have investigated the mechanism of PRIMA-1MET/APR-246-induced 
apoptosis with focus on the mitochondrial and death receptor pathways. We showed 
that PRIMA-1MET/APR-246 induces mutant p53-dependent mitochondria-mediated 
apoptosis through early activation of caspase-2, followed by ∆ψm loss, cytochrome c 
release, further activation of downstream caspase-9 and -3, and apoptosis.  
 
Mutant p53-dependent induction of PUMA and Bax by PRIMA-1MET/APR-246 forms 
a parallel signaling pathway converging on mitochondria. Inhibiting activation of 
caspase-2 or knocking down PUMA simultaneously did not enhance inhibition of ∆ψm 
loss and apoptosis, as compared to knocking down only one of them, suggesting that 
they function in the same pathway and other mutant p53-dependent pathways may be 
activated by PRIMA-1MET/APR-246. 
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Paper II 
 
Mutant p53 targeting by the low molecular weight compound 
STIMA-1. 
 
It has been demonstrated that compounds with structural resemblance to  CP-31398 
possess activity against tumor cells. Therefore we synthesized a number of 2-
styrylquinazolin-4-(3H)-one-related molecules and performed a cell-based screening to 
check the effect on mutant p53-dependent growth suppression. STIMA-1 was 
identified as the most potent molecule. It has Michael acceptor activity and can 
potentially react with thiol groups in cellular proteins. Here we aimed at a detailed 
characterization of STIMA-1 with regard to its ability to target mutant p53.  
 
We asked whether STIMA-1 can form adducts with cysteines. We first incubated 
STIMA-1 with the cysteine analog N-acetylcysteine (NAC) and detected formation of 
adducts. The cell growth suppression induced by STIMA-1 could be blocked by 
preincubation with NAC. Compared to STIMA-1, the growth suppression effect by the 
structurally related compound CP-31398 was only partially blocked by NAC.  
 
We observed a reduced number of free thiol groups in recombinant mutant p53 protein 
after incubation with STIMA-1 using a maleimide binding assay. The number free thiol 
groups also reduced in STIMA-1 treated mutant p53-expressing cells.  
 
We also found that STIMA-1 upregulates p53 target genes,  suppresses cell growth, and 
triggers caspase activation and cell death in a mutant p53-dependent manner, in 
contrast to cisplatin and CP-31398. Tumor cells expressing mutant p53 are more 
sensitive to STIMA-1 than wt p53-expressing tumor cells, p53 null tumor cells, or 
human diploid fibroblasts. Switching off mutant p53 expression in tumor cells by 
doxycyclin made the cells more resistant to STIMA-1 treatment, confirming that the 
effect of STIMA-1 is mutant p53-dependent. Finally we showed that mutant p53 DNA 
binding is stimulated after incubation with STIMA-1. 
 
In conclusion, we have identified STIMA-1, a low molecular weight compound and 
Michael acceptor that targets mutant p53 expressing tumor cells and restores 
suppression of cell growth and apoptosis activities to mutant p53. This rases the 
possibility that thiol group modification plays a role in mutant p53 reactivation and 
might give us a lead to develop mutant p53 targeting anti-cancer drugs.  
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Paper III 
 
PRIMA-1MET/APR-246 targets mutant forms of p53 family 
members p63 and p73. 
 
In this paper, we investigated whether PRIMA-1MET/APR-246 can restore wild type 
function to mutant p63 and p73 and trigger apoptosis in tumor cells. We first tested the 
effect of PRIMA-1MET/APR-246 on different isoforms of temperature sensitive p63 and 
p73 in H1299 cells. We found upregulation of p63/ p73 target genes p21 and PUMA at 
both mRNA and protein level in p63γ and p73β-expressing cells. In contrast, p73α 
expressing cells were not very sensitive to PRIMA-1MET/APR-246 treatment. We also 
found that the treatment leads to supression of cell proliferation, activation of caspases 
and increased cell death in mutant p63γ and p73β-expressing cells, but has less effect on 
TAp73α.  
 
We next generated Saos-2 cells stably expressing Tet-inducible TAp63γ-R204W or 
TAp63γ-R304W. We observed that PRIMA-1MET/APR-246 treatment triggered cell 
growth supression in cells expressing TAp63γ-R204W or TAp63γ-R304W. Moreover, 
treatment with PRIMA-1MET/APR-246 induced apoptosis (induction of subG1 
population and active caspases) in TAp63γ-R304W expressing cells. This effect was 
more pronounced in the presence than in the absence of doxycycline for the TAp63γ-
R304W cells. For the TAp63γ-R204W-expressing cells, we observed a significant G1 
cell cycle arrest and a decreased S-phase fraction, indicating that this mutant promotes 
cell cycle arrest in response to PRIMA-1MET/APR-246 treatment. 
 
We previously found that PRIMA-1MET/APR-246 treatment causes a nucleolar 
accumulation of mutant p53 along with PML. Here we also examined whether PRIMA-
1MET/APR-246 affects the subcellular localization of mutant p63. Treatment with 
PRIMA-1MET/APR-246 induced a redistribution of both p63 mutants partially to PML-
NBs and nucleoli.  
 
To examine the DNA binding of mutant p63, we incubated nuclear lysate of PRIMA-
1MET/APR-246 treated TAp63γ-R204W and TAp63γ-R304W cells with p53 consensus 
binding oligo nucleotides. We observed an increased binding of p63 to DNA in PRIMA-
1MET/APR-246-treated cells. In addition, we also found that p63 downstream targets p21, 
Noxa and keratin 14 were induced in PRIMA-1MET/APR-246 treated TAp63γ-R204W 
and TAp63γ-R304W cells. The induction of keratin 14 protein expression after treatment 
with PRIMA-1MET/APR-246 was only observed at PRIMA-1MET/APR-246 
concentrations that did not induce apoptosis. 
We conclude that PRIMA-1MET/APR-246 can restore the wild type function to mutant 
p63 and p73, that share high sequence homology of DNA-binding domains with p53. 
Treatment with PRIMA-1MET/APR-246 triggered cell growth suppression and apoptosis 
in mutant p73 or p63 expressing cells. Thus, our analysis demonstrates significant 
differences among mutant p63 and p73 isoforms with respect to their ability to confer an 
apoptotic response to PRIMA-1MET/APR-246. 
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Paper IV 
 
PRIMA-1 MET targets endogenous mutant p63 and enhances 
keratinocyte differentiation 
 
We have shown in paper III that PRIMA-1MET/APR-246 can restore pro-apoptotic 
activity to mutant isoforms of TAp63γ in human tumor cells. However, we wished to 
test the effect of PRIMA-1MET/APR-246 on mutant p63 in a more physiological setting. 
∆Np63α, which shares same DBD as TAp63γ is found dominately expressed in the 
basal layer of epidermis and it plays an important role in stem cell maintanance and 
differentiation. The mutations in p63α  are associated with a number of human 
developmental defect syndromes. Here we address the question whether PRIMA-
1MET/APR-246 could reactivate endogenous mutant p63α in human keratinocytes 
derived from patients with the EEC syndrome and whether it can stimulate keratinocyte 
differentiation. 
 
We first discovered that PRIMA-1MET/APR-246 promoted differentiation in both 
p63α R204W and R304W expressing keratinocytes.  Cells formed tighter cell-cell 
contacts, changed to flattened or elongated cell morphology and a three-dimensional 
organization with stratified cell layers in a manner similar to differentiated wt p63 
expressing cells. The untreated mutant p63 expressing keratinocytes only form mono 
layer in differentiation culture. After treatment, the differentiation morphology in p63 
R204W expressing cells is not as pronounced as p63 R304W expressing keratinocytes. 
It is plausible that p63 R304W mutant is easier to be rescued by PRIMA-1MET/APR-
246 than p63 R204W mutant. However, we can not exclude that inter-individual 
variation in the response to PRIMA-1MET/APR-246 and a limited number of patients 
have affected our results. 
 
We then observed that K1, K10, Involucrin and TGS, which are involved in classical 
epidermal differentiation are upregulated in mutant p63-expressing cells upon PRIMA-
1MET/APR-246 treatment. All these observations suggest restoration of keratinocytes 
differentiation. Claudin-1, a ∆Np63α target gene is also induced by PRIMA-
1MET/APR-246. This suggests that the transcription transactivation activity of ∆Np63α 
is restored by PRIMA-1MET/APR-246.  
 
Our preliminary data showed that PRIMA-1MET/APR-246 also promoted cell 
proliferation. Flores’ papers showed that TAp63 is essential for maintenance of 
epidermal and dermal precursors. The hair follicle-associated dermal and epidermal 
cells from TAp63 null mice undergo senescence. Therefore it is also plausible that 
PRIMA-1MET/APR-246 treatment may rescue ability of mutant TAp63 to maintain cell 
proliferation. Thus the increased cell density will also promote differentiation 
machinery (Figure 6).  
  
Thus we demonstrate that PRIMA-1MET/APR-246 is not only targeting exogenous 
mutant p63 in a tumor cell background and promote mutant p63-dependent cell death 
by apoptosis, but it also rescuing  endogenous mutant p63 in a physiological context 
where functional p63 is essential for normal differentiation. Our study raises the 
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possibility for improved treatment of EEC syndrome patients by mutant p63 rescue in 
the future. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Model for enhanced differentiation in mutant p63 expressing 
keratinocytes by PRIMA-1MET/APR-246. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mutant p63     wild type p63 
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CONCLUSIONS  
 
Paper I 
PRIMA-1MET induces mitochondrial apoptosis via activation 
of caspase-2 
 
• PRIMA-1MET/APR-246 triggers apoptosis in a mutant p53 dependent manner. 
 
• PRIMA-1MET/APR-246 induces caspase 2 activation and loss of ∆ψm in several 
tumor cell lines expressing different hot spot mutant p53. 
 
• PRIMA-1MET/APR-246 treatment rescues wild type function to mutant p53 and 
induces p53 target genes: PIDD, Bax and PUMA. 
 
• BH3 family members (Bax and PUMA), along with active caspase 2 are 
essential upstream signaling for triggering mitochondrial apoptosis pathway. 
 
• Release of cytochrome c from mitochondria leads to activation of caspase-9, 
followed by activation of caspase-3 and finally cell death. 
 
• Inhibition or silencing caspase-2 rescues cell death in mutant p53 expressing 
cells treated with PRIMA-1MET/APR-246. 
 
 
Paper II 
Mutant p53 targeting by the low molecular weight compound 
STIMA-1 
 
• STIMA-1 induces mutant p53-dependent growth suppression and apoptosis in 
Saos-2-His273 and H1299-His175 cells. 
 
• Mutant p53 expressing cells are more sensitive to STIMA-1 than wild type p53 
expressing or p53 null cells.  
 
• STIMA-1 binds to thiol groups in both recombinant mutant p53 and mutant p53 
expressing cells. 
 
• Pre-incubation with N-acetylcysteine blocks cell growth inhibition effect of 
STIMA-1, but not CP-31398. 
 
• STIMA-1 improves DNA binding ability of mutant p53 and induces p53 target 
genes PUMA, p21 and Bax. 
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Paper III  
PRIMA-1MET/APR-246 targets mutant forms of p53 family 
members p63 and p73 
 
• PRIMA-1MET/APR-246 treatment inhibits cells growth and induces apoptosis in 
H1299 cells expressing tsp63γ and tsp73β, but not H1299 cells expressing 
tsp73α. 
  
• PRIMA-1MET/APR-246 treatment induces p53/ p63 target gene p21 in H1299 
cells expressing tsp63γ and tsp73β. 
 
• PRIMA-1MET/APR-246 inhibits cell proliferation in Saos-2 cells expressing 
TAp63γ R304W or TAp63γ R204W. 
 
• The induction of TAp63γ R304W or TAp63γ R204W sensitizes cells for 
apoptosis or G1 cell cycle arrest after PRIMA-1MET/APR-246 treatment. 
 
• PRIMA-1MET/APR-246 improves DNA binding capacity of TAp63γ R304W 
and TAp63γ R204W. 
 
• The mRNA and protein level of Noxa and p21 are induced in mutant p63 
expressing cells after PRIMA-1MET/APR-246 treatment. 
 
• Epidermis basal layer marker Keratin 14 is induced in PRIMA-1MET/APR-246 
treated TAp63γ R204W cells. 
 
 
Paper IV  
PRIMA-1MET targets endogenous mutant p63 and enhances 
keratinocyte differentiation 
 
• PRIMA-1MET/APR-246 improves cells stratification in endogenous mutant 
p63α expressing keratinocytes. 
 
• PRIMA-1MET/APR-246 treatment induces expression of differentiation markers 
(K1, K10, CYS_ME, involucrin and Transglutaminase) at mRNA and protein 
level in mutant p63 expressing cells. 
 
• p63 target gene Claudin-1 is upregulated in mutant p63 expressing cells after 
PRIMA-1MET/APR-246 treatment. 
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SUMMARY 
 
We showed that the low molecular weight compound PRIMA-1MET/APR-246 
reactivate mutant p53 family members (p53, p63 and p73), that share high homology 
especially in the DNA binding domain. PRIMA-1MET/APR-246 stimulated DNA 
binding of mutant p53 and p63, restored the pro-apoptotic activities to mutant p53 
family members and triggered apoptosis in cultured tumor cells. Furthermore, PRIMA-
1MET/APR-246 reactivated mutant p63α promotes differentiation of human 
keratinocytes derived from patients carrying endogenous mutant p63. These results 
indicate that PRIMA-1MET/APR-246 interacts with the homologous structures in mutant 
p53 family proteins and thus restores common functional defects.  
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